Insperity Stock Down 55% From Highs as Hedge Fund Buys $13 Million Stake — Is It A Turnaround Bet?

Stadium Capital disclosed a new $13.0M position in Insperity (263,715 shares) in a 13F filing, representing 13.9% of its $93.6M reportable U.S. equity assets as of Sept. 30 and making NSP its fourth-largest holding. Insperity shares trade at $35.37, down 55% year-over-year; the company reported revenue of $1.6B last quarter (up 4% year/year) but logged a $20M net loss and adjusted EBITDA of $10M due to elevated healthcare costs. Management highlights cost controls and a multi-year UnitedHealthcare agreement that lowers large-claim pooling to $500k beginning in 2026, which Stadium appears to be betting will materially improve margins and reset earnings trajectory.

Analysis

Market structure: Stadium’s $13M stake in NSP (13.9% of its 13F U.S. equity book) highlights value hunting in beaten-down HR outsourcing names; NSP is -55% Y/Y and trades like a distressed asset despite $6.8B TTM revenue and a 7% yield. Winners include reinsurers/TPAs (UnitedHealthcare reduces NSP large-claim volatility) and income-oriented funds; losers are short-term equity holders and any small competitors unable to absorb rising healthcare costs. Cross-asset flows should modestly favor equity-income demand and elevated options IV while corporate credit impact is minimal unless claims blow out.

Risk assessment: Tail risks — catastrophic claim clusters, contract renegotiation failure, or regulatory reclassification of PEOs — could wipe out cash and force dividend cuts; probability low-to-medium but impact high. Time horizons matter: days-weeks = volatility around earnings; months = management’s cost-control progress; 12–24 months = realized benefit from UHC pooling change (effective 2026). Hidden dependencies: reinsurance pricing, client churn from SMB stress, and claims latency; catalysts include quarterly adjusted EBITDA trends and 2025 guidance updates.

Trade implications: Direct: accumulate NSP below $40, scale on weakness < $30, target ~$60 within 12–24 months if margins normalize; consider buying long-dated calls (Jan 2027 40C) for leveraged exposure. Pair: long NSP / short PAYX (PAYX) to hedge payroll-volume cyclicality; options: sell Jan 2025 $30 puts to collect premium and set a low-cost basis if comfortable owning at ~15% discount. Rotate modest allocation from low-yield industrials into high-yield HR outsourcing in 1–3% increments.

Contrarian angles: Consensus prices in structural decline but may underweight the 2026 contract tailwind — if large-claim pooling drops to $500k, loss frequency volatility could fall >30%, restoring margins. Reaction could be underdone (big upside if management executes) or overdone (permanent margin erosion if claim trends persist). Historical analog: insurer recoveries post-reinsurance program re-pricing often see 50–100% equity rebounds within 12–24 months when loss trends stabilize. Unintended consequence: tighter reinsurance could cap upside if NSP pays materially higher premium, so validate net benefit in successive guidance releases.

Key Decisions for Investors

• Establish a staged long position in NSP: initial 2% portfolio weight at market price ≤ $40, add to 4% if price < $30; set stop-loss at $28 and a 12–24 month target exit at $60 (≈70% upside from $35.37) if adjusted EBITDA margins recover.
• Buy leveraged, limited-risk exposure: purchase Jan 2027 NSP 40 calls sized to 0.5% portfolio risk or, if premium too rich, execute a 2-year call spread (buy 40C / sell 60C) to cap cost; horizon to 2026 implementation of UHC pooling.
• Income/entry alternative: sell Jan 2025 NSP $30 puts up to a notional 1–2% portfolio allocation to collect premium and potentially acquire NSP at ~15% discount; do not sell if implied vol < realized by >20%.
• Pair trade hedge: run long NSP (2%) vs short PAYX (1%) to isolate idiosyncratic recovery; reassess after two quarterly reports—close short if PAYX outperforms by >10% relative to NSP or if sector-wide margin signals change.
• Hard triggers to act: add >50% to long position if (a) adjusted EBITDA turns positive and increases sequentially for two quarters, or (b) management quantifies net savings from UHC deal >$0.10/sh for 2026; liquidate if management cuts dividend or guidance implies >10% additional margin erosion.